Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Communication
  • Published:

Downregulation of Sef, an inhibitor of receptor tyrosine kinase signaling, is common to a variety of human carcinomas

Abstract

Carcinomas are tumors of epithelial origin accounting for over 80% of all human malignancies. A substantial body of evidence implicates oncogenic signaling by receptor tyrosine kinases (RTKs) in carcinoma development. Here we investigated the expression of Sef, a novel inhibitor of RTK signaling, in normal human epithelial tissues and derived malignancies. Human Sef (hSef) was highly expressed in normal epithelial cells of breast, prostate, thyroid gland and the ovarian surface. By comparison, substantial downregulation of hSef expression was observed in the majority of tumors originating from these epithelia. Among 186 primary carcinomas surveyed by RNA in situ hybridization, hSef expression was undetectable in 116 cases including 72/99 (73%) breast, 11/16 (69%) thyroid, 16/31 (52%) prostate and 17/40 (43%) ovarian carcinomas. Moderate reduction of expression was observed in 17/186, and marked reduction in 40/186 tumors. Only 13/186 cases including 12 low-grade and one intermediate grade tumor retained high hSef expression. The association of hSef downregulation and tumor progression was statistically significant (P<0.001). Functionally, ectopic expression of hSef suppressed proliferation of breast carcinoma cells, whereas inhibition of endogenous hSef expression accelerated fibroblast growth factor and epidermal growth factor-dependent proliferation of cervical carcinoma cells. The inhibitory effect of hSef on cell proliferation combined with consistent downregulation in human carcinoma indicates a tumor suppressor-like role for hSef, and implicates loss of hSef expression as a common mechanism in epithelial neoplasia.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

Accession codes

Accessions

GenBank/EMBL/DDBJ

Abbreviations

EOC:

epithelial ovarian cancers

GG:

Gleason grade

OSE:

ovarian surface epithelium

RTK:

receptor tyrosine kinase

Sef:

similar expression to FGF genes

References

  • Bell DA . (2005). Origins and molecular pathology of ovarian cancer. Mod Patho 18: S19–S32.

    Article  CAS  Google Scholar 

  • Blume-Jensen P, Hunter T . (2001). Oncogenic kinase signalling. Nature 411: 355–365.

    Article  CAS  PubMed  Google Scholar 

  • Darby S, Sahadevan K, Khan MM, Robson CN, Leung HY, Gnanapragasam VJ . (2006). Loss of Sef (similar expression to FGF) expression is associated with high grade and metastatic prostate cancer. Oncogene 25: 4122–4127.

    Article  CAS  PubMed  Google Scholar 

  • De Marzo AM, Coffey DS, Nelson WG . (1999). New concepts in tissue specificity for prostate cancer and BPH. Urology 53: 29–39.

    Article  CAS  PubMed  Google Scholar 

  • Furthauer M, Lin W, Ang SL, Thisse B, Thisse C . (2002). Sef is a feedback-induced antagonist of Ras/MAPK-mediated FGF signalling. Nat Cell Biol 4: 170–174.

    Article  CAS  PubMed  Google Scholar 

  • Gimm O . (2001). Thyroid Cancer. Cancer Lett 163: 143–156.

    Article  CAS  PubMed  Google Scholar 

  • Grose R, Dickson C . (2005). Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 16: 179–186.

    Article  CAS  PubMed  Google Scholar 

  • Harduf H, Halperin E, Reshef R, Ron D . (2005). Sef is synexpressed with FGFs during chick embryogenesis and its expression is differentially regulated by FGFs in the developing limb. Dev Dyn 233: 301–312.

    Article  CAS  PubMed  Google Scholar 

  • Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al. (2006). Cancer statistics, 2006. CA Cancer J Clin 56: 106–130.

    Article  PubMed  Google Scholar 

  • Kosary CL . (1994). FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 10: 31–46.

    Article  CAS  PubMed  Google Scholar 

  • Matsumoto S, Kasumi F, Sakamoto G, Onda M, Nakamura Y, Emi M . (1997). Detailed deletion mapping of chromosome arm 3p in breast cancers: a 2-cM region on 3p14.3-21.1 and a 5-cM region on 3p24.3-25.1 commonly deleted in tumors. Genes Chromosomes Cancer 20: 268–274.

    Article  CAS  PubMed  Google Scholar 

  • Normanno N, Bianco C, Strizzi L, Mancino M, Maiello MR, De Luca A et al. (2005). The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 6: 243–257.

    Article  CAS  PubMed  Google Scholar 

  • Preger E, Ziv I, Shabtay A, Sher I, Tsang M, Dawid IB et al. (2004). Alternative splicing generates an isoform of the human Sef gene with altered subcellular localization and specificity. Proc Natl Acad Sci USA 101: 1229–1234.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shaoul E, Reich-Slotky R, Berman B, Ron D . (1995). Fibroblast growth factor receptors display both common and distinct signaling pathways. Oncogene 10: 1553–1561.

    CAS  PubMed  Google Scholar 

  • Sher I, Zisman-Rozen S, Eliahu L, Whitelock JM, Maas-Szabowski N, Yamada Y et al. (2006). Targeting perlecan in human keratinocytes reveals novel roles for perlecan in epidermal formation. J Biol Chem 281: 5178–5187.

    Article  CAS  PubMed  Google Scholar 

  • Tavassoli FA, Devilee P . (2003). Genetics of Tumors of the Breast, and Female Genital Organs. IARC Press, pp 18.

    Google Scholar 

  • Thompson N, Lyons J . (2005). Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 5: 350–356.

    Article  CAS  PubMed  Google Scholar 

  • Torii S, Kusakabe M, Yamamoto T, Maekawa M, Nishida E . (2004). Sef is a spatial regulator for Ras/MAP kinase signaling. Dev Cell 7: 33–44.

    Article  CAS  PubMed  Google Scholar 

  • Tsang M, Friesel R, Kudoh T, Dawid IB . (2002). Identification of Sef, a novel modulator of FGF signalling. Nat Cell Biol 4: 165–169.

    Article  CAS  PubMed  Google Scholar 

  • Xiong S, Zhao Q, Rong Z, Huang G, Huang Y, Chen P et al. (2003). hSef Inhibits PC-12 cell differentiation by interfering with Ras-mitogen-activated protein kinase MAPK signaling. J Biol Chem 278: 50273–50282.

    Article  CAS  PubMed  Google Scholar 

  • Yang RB, Ng CK, Wasserman SM, Komuves LG, Gerritsen ME, Topper JN . (2003). A novel IL-17 receptor-like protein identified in human umbilical vein endothelial cells antagonizes basic fibroblast growth factor-induced signaling. J Biol Chem 278: 33232–33238.

    Article  CAS  PubMed  Google Scholar 

  • Ziv I, Fuchs Y, Preger E, Shabtay A, Zilpa T, Dym N et al. (2006). Human Sef-a isoform utilizes different mechanisms to regulate RTK signaling pathways and subsequent cell fate. J Biol Chem 281: 39225–39235.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank Sharon Lubinsky-Mink and Dr Orit Goldsmidt for excellent technical assistance. This work was supported by grants from the ICRF (# 2004973), and the Israel Ministry of Health (# 1005314) to Dina Ron.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to D Ron.

Additional information

Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zisman-Rozen, S., Fink, D., Ben-Izhak, O. et al. Downregulation of Sef, an inhibitor of receptor tyrosine kinase signaling, is common to a variety of human carcinomas. Oncogene 26, 6093–6098 (2007). https://doi.org/10.1038/sj.onc.1210424

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1210424

Keywords

This article is cited by

Search

Quick links